| 产品描述: | BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist. Target: Angiotensin Receptor in vitro: BIBS 39 displaces [125I] AII from its specific binding sites with a Ki value of 29 ± 7 nM for the AII subtype 1 (AT1) receptor and a Ki value of 480 ± 110 nM for the AII subtype 2 (AT2) receptor. BIBS 222 shows a Ki value of 20 ± 7 nM for the AT1 subtype and a Ki value of 730 ± 170 nM for the AT2 subtype. BIBS 39 is 17 times more selective for the AT1 subtype and BIBS 222 37 times. BIBS 39 shifts the AII concentration-contractile response curves in isolated rabbit aorta to the right in a parallel fashion. in vivo: In pithed rats, BIBS 39 dependently shifts the dose-response curve of AII to the right without affecting the maximal response. BIBS 222 also causes parallel shifts to the right but a significant reduction of the maximal responses was observed at 3 and 10 mg/kg i.v. These results show that the benzimidazole derivatives BIBS 39 is a potent and selective AII receptor antagonists. Substitution with a benzimidazole moiety results into a considerable loss of selectivity for the AT1 receptor subtype compared with an imidazole moiety as, for instance, in DuP 753.BIBS 39 is a new nonpeptide angiotensin receptor blockers that has affinity for both AT1- and AT2-receptors, is also a potent antagonist of the cardiovascular effects of AII in pithed rabbits. |
| 靶点: |
Angiotensin Receptor;RAAS |
| 细胞实验: |
用 H2O 作为溶剂配制的母液,过滤除菌后,可以直接用培养基稀释到所需的工作液浓度。 用 DMSO 作为溶剂配制的母液,在稀释时要确保工作液中 DMSO 的终浓度尽量在 0.1% 以下,最高不要超过 0.5% ,并设置相应浓度的 DMSO 对照组。临用前将培养基和DMSO母液预热至37℃或以上温度后进行稀释。 |
| 动物实验: |
方案 一 请依序添加每种溶剂: 10% DMSO+ 40% PEG300+ 5% Tween-80+ 45% Saline 。Solubility: 1.25 mg/mL (2.38 mM); 悬浊液; 超声助溶 此方案可获得 1.25 mg/mL的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL。 生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。 方案 二 请依序添加每种溶剂: 10% DMSO+ 90% (20% SBE-β-CD in Saline) 。Solubility: 1.25 mg/mL (2.38 mM); 悬浊液; 超声助溶 此方案可获得 1.25 mg/mL的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。 2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。 注意事项:对于正常小鼠或大鼠,建议 DMSO 的终浓度不要大于 10%;对于裸鼠或体弱小鼠或大鼠,建议 DMSO 的终浓度尽量不要超过 2%;对于正常小鼠,如果给药频率超过一天三次,建议 DMSO 的终浓度尽量不要超过 5%。 |
| 参考文献: |
1. Zhang J, et al. Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists. Eur J Pharmacol. 1992 Jul 21;218(1):35-41. 2. Zhang J, et al. Hemodynamic effects of angiotensin II and the influence of angiotensin receptor antagonists in pithed rabbits. J Cardiovasc Pharmacol. 1995 May;25(5):724-31. |
| 溶解性: |
DMSO:16mg/ml 请分装保存,避免反复冻融造成的产品失效。-80°C储存时,请在2年内使用,-20°C储存时,请在1年内使用。 |
| 保存条件: |
2-8℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.906 ml |
9.53 ml |
19.06 ml |
| 5 mM |
0.381 ml |
1.906 ml |
3.812 ml |
| 10 mM |
0.191 ml |
0.953 ml |
1.906 ml |
| 50 mM |
0.038 ml |
0.191 ml |
0.381 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |